Skip to content

Clinical Observation on the Efficacy of Wenyang Yishen Tongluo Decoction in Treating Rheumatoid Arthritis with Osteoporosis

Clinical Observation on the Efficacy of Wenyang Yishen Tongluo Decoction in Treating Rheumatoid Arthritis with Osteoporosis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085354
Enrollment
Unknown
Registered
2024-06-05
Start date
2024-06-10
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis and osteoporosis

Interventions

Control group:For basic treatment, Gushukang capsule was taken orally, 4 capsules/time, twice a day.
Treatment group:Basic treatment plus Wenyang Yishen Tongluo Recipe, 3 times a day.

Sponsors

Yunnan Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The patient also met the diagnostic criteria of rheumatoid arthritis specified by American College of Rheumatology in 2010 and the diagnostic criteria of osteoporosis in Expert Consensus of Diagnostic Criteria for Osteoporosis in China; 2. Patients are 40-75 years old, male or female; 3. No serious liver and kidney function damage, diabetes, thyroid and parathyroid diseases; 4. Volunteer to participate in the project study and cooperate to sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1. Patients with serious endocrine system diseases, digestive system diseases, blood diseases, nervous system diseases and other possible secondary osteoporosis diseases; 2. Patients who have taken hormone for more than 1 month and cannot stop taking the drug; 3. Complicated with serious organ damage or mental disorder. 4. Allergic constitution and allergic to this medicine or its ingredients; 5. Pregnant or lactating women: 6. Patients with severe bone destruction, joint deformity, stiffness and joint dysfunction in the late stage of repeated attack.

Design outcomes

Primary

MeasureTime frame
DAS28 score;Osteoporosis four items;peripheral bone mineral density;TCM Symptom Points;Serum rheumatoid factor;Anti-CCP antibodies;

Secondary

MeasureTime frame
Serum rheumatoid factor;Anti-cyclic citrullinated peptide antibody;Bone mineral density of lumbar vertebrae;Erythrocyte sedimentation rate, ESR;C-reactive protein, CRP;Routine blood testing;calcium;bone alkaline phosphatase;

Countries

China

Contacts

Public ContactPeng Jiangyun

Yunnan Hospital of Traditional Chinese Medicine

pengjiangyun@126.com+86 130 9996 3399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026